Literature DB >> 19669240

Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C.

Takahisa Sato1, Ryosuke Tateishi, Haruhiko Yoshida, Takamasa Ohki, Ryota Masuzaki, Jun Imamura, Tadashi Goto, Fumihiko Kanai, Shuntaro Obi, Naoya Kato, Shuichiro Shiina, Takao Kawabe, Masao Omata.   

Abstract

BACKGROUND AND AIMS: Ultrasonography is the most frequently used modality in surveillance for HCC among patients with chronic hepatitis C. However, the optimal surveillance interval is still controversial and the usefulness of supplementary tumor marker determination has not been confirmed.
METHODS: A total of 243 cases of naive HCC were detected among 1,431 patients with chronic hepatitis C under outpatient-based surveillance. The mode of HCC detection, including ultrasound surveillance interval, was retrospectively examined and the relation between the interval and detected tumor size was analyzed. Tumor volume doubling time was estimated from exponential increase in serum tumor marker levels when applicable.
RESULTS: HCC was first detected by ultrasonography in 221 patients. Ultrasound surveillance interval, ranging between 2 and 8 months, was not correlated with the size of tumor at detection. Patients with cirrhosis were likely to be surveyed at shorter intervals. The size of tumor exceeded 30 mm only in three (1.4%) cases. They were all positive for a biomarker and the estimated tumor doubling time was short. In 14 cases, HCC was first detected by CT indicated by abnormal rise in tumor marker levels despite negative ultrasound findings. In the remaining eight cases, ultrasonography had been replaced by CT as surveillance modality because of excessive obesity or coarseness of liver parenchyma.
CONCLUSIONS: Ultrasound surveillance at 6-month intervals was appropriate in general for the detection of HCC at a size smaller than 30 mm. However, in patient with established cirrhosis, more frequent screening would be needed to detect tumors of the same size.

Entities:  

Year:  2009        PMID: 19669240      PMCID: PMC2790585          DOI: 10.1007/s12072-009-9145-y

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  30 in total

1.  Alphafetoprotein: an obituary.

Authors:  M Sherman
Journal:  J Hepatol       Date:  2001-04       Impact factor: 25.083

2.  Focal liver lesions: pattern-based classification scheme for enhancement at arterial phase CT.

Authors:  M Nino-Murcia; E W Olcott; R B Jeffrey; R L Lamm; C F Beaulieu; K A Jain
Journal:  Radiology       Date:  2000-06       Impact factor: 11.105

3.  Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience.

Authors:  M F Yuen; C C Cheng; I J Lauder; S K Lam; C G Ooi; C L Lai
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

4.  A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

Authors:  Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Ryosuke Tateishi; Tomonori Fujishima; Takashi Ishikawa; Yukihiro Koike; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

5.  Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status.

Authors:  F Trevisani; P E D'Intino; A M Morselli-Labate; G Mazzella; E Accogli; P Caraceni; M Domenicali; S De Notariis; E Roda; M Bernardi
Journal:  J Hepatol       Date:  2001-04       Impact factor: 25.083

Review 6.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 7.  Hepatocellular carcinoma: recent trends in Japan.

Authors:  Kendo Kiyosawa; Takeji Umemura; Tetsuya Ichijo; Akihiro Matsumoto; Kaname Yoshizawa; Amal Gad; Eiji Tanaka
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

8.  Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis.

Authors:  Alessandro Cucchetti; Marco Vivarelli; Fabio Piscaglia; Bruno Nardo; Roberto Montalti; Gian Luca Grazi; Matteo Ravaioli; Giuliano La Barba; Antonino Cavallari; Luigi Bolondi; Antonio Daniele Pinna
Journal:  J Hepatol       Date:  2005-08       Impact factor: 25.083

9.  Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan.

Authors:  Chien-An Sun; Der-Min Wu; Chia-Chin Lin; Sheng-Nan Lu; San-Lin You; Li-Yu Wang; Mei-Hsuan Wu; Chien-Jen Chen
Journal:  Am J Epidemiol       Date:  2003-04-15       Impact factor: 4.897

10.  Randomized controlled trial of screening for hepatocellular carcinoma.

Authors:  Bo-Heng Zhang; Bing-Hui Yang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

View more
  21 in total

Review 1.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

2.  Management of hepatocellular carcinoma: Enlightening the gray zones.

Authors:  Andrea Mancuso
Journal:  World J Hepatol       Date:  2013-06-27

3.  Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis.

Authors:  Kristina Tzartzeva; Joseph Obi; Nicole E Rich; Neehar D Parikh; Jorge A Marrero; Adam Yopp; Akbar K Waljee; Amit G Singal
Journal:  Gastroenterology       Date:  2018-02-06       Impact factor: 22.682

Review 4.  Surveillance for hepatocellular carcinoma.

Authors:  Jeyamani Ramachandran
Journal:  J Clin Exp Hepatol       Date:  2014-04-21

5.  Phenotype-dependent production of des-γ-carboxy prothrombin in hepatocellular carcinoma.

Authors:  Hideto Suzuki; Kazumoto Murata; Takaya Gotoh; Masao Kusano; Hiroshi Okano; Takashi Oyamada; Yoshikazu Yasuda; Masatoshi Imamura; Masatoshi Kudo; Masashi Mizokami; Atsushi Sakamoto
Journal:  J Gastroenterol       Date:  2011-07-09       Impact factor: 7.527

6.  Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C.

Authors:  Charlotte E Costentin; Philippe Sogni; Bruno Falissard; Jean-Claude Barbare; Noelle Bendersky; Olivier Farges; Nathalie Goutte
Journal:  Dig Dis Sci       Date:  2019-07-25       Impact factor: 3.199

7.  Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.

Authors:  Robert G Gish; Richard S Finn; Jorge A Marrero
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-04

Review 8.  Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.

Authors:  Claus Niederau
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

Review 9.  Role of stereotactic body radiation therapy for hepatocellular carcinoma.

Authors:  Naoko Sanuki; Atsuya Takeda; Etsuo Kunieda
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

Review 10.  Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it?

Authors:  Edoardo G Giannini; Alessandro Cucchetti; Virginia Erroi; Francesca Garuti; Federica Odaldi; Franco Trevisani
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.